Cines, Douglas B.
Gernsheimer, Terry
Wasser, Jeffrey
Godeau, Bertrand
Provan, Drew
Lyons, Roger
Altomare, Ivy
Wang, Xuena
Lopez, Angela
Funding for this research was provided by:
Amgen Inc.
Article History
Received: 22 April 2015
Revised: 6 July 2015
Accepted: 7 July 2015
First Online: 23 July 2015
Compliance with ethical standards
:
: This study was funded by Amgen. Douglas B. Cines has been a consultant for Amgen, GlaxoSmithKline, Symphogen, Cangene, Rigel, and Eisai. Terry Gernsheimer is a consultant for Amgen, Symphogen, Clinical Options, GlaxoSmithKline, and Cangene; received honoraria from Amgen, Laboratorios Raffo SA, and Hemedicus Corporation; and received research funding from Shionogi. Jeffrey Wasser has served on the advisory board and speaker’s bureau for Amgen and is also a consultant for Amgen. Bertrand Godeau is a consultant for Amgen, GlaxoSmithKline, LFB, and Roche and has received research funding from Roche. Drew Provan has honoraria from GlaxoSmithKline and Amgen and is a stockholder of GlaxoSmithKline. Roger Lyons is a consultant for Amgen. Ivy Altomare has served on the advisory board and speaker’s bureau for Amgen. Xuena Wang is an employee of and shareholder in Amgen; Angela Lopez was an employee of and is a shareholder in Amgen.
Free to read: This content has been made available to all.